$INGN
Inogen Inc

2014 Q3 Form 10-Q Financial Statement

#000156459014005531 Filed on November 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2013 Q4 2013 Q3
Revenue $29.39M $19.76M $19.78M
YoY Change 48.62% 43.2% 49.83%
Cost Of Revenue $14.74M $9.600M $6.751M
YoY Change 118.4% 41.18% 0.76%
Gross Profit $14.65M $10.18M $9.642M
YoY Change 51.93% 45.36% 48.34%
Gross Profit Margin 49.84% 51.49% 48.75%
Selling, General & Admin $10.28M $9.000M $8.082M
YoY Change 27.25% 42.86% 46.95%
% of Gross Profit 70.2% 88.45% 83.82%
Research & Development $798.0K $600.0K $700.0K
YoY Change 14.0% 20.0% 16.67%
% of Gross Profit 5.45% 5.9% 7.26%
Depreciation & Amortization $3.148M $2.540M $2.274M
YoY Change 38.43% 66.01% 83.39%
% of Gross Profit 21.49% 24.96% 23.58%
Operating Expenses $11.08M $9.600M $8.756M
YoY Change 26.56% 41.18% 45.93%
Operating Profit $3.567M $575.0K $886.0K
YoY Change 302.6% 187.5% 77.2%
Interest Expense $104.0K -$300.0K $113.0K
YoY Change -7.96% 200.0% -156.5%
% of Operating Profit 2.92% -52.17% 12.75%
Other Income/Expense, Net -$93.00K $0.00 -$69.00K
YoY Change 34.78%
Pretax Income $3.474M $200.0K $817.0K
YoY Change 325.21% 100.0% 308.5%
Income Tax $1.341M -$21.70M $43.00K
% Of Pretax Income 38.6% -10850.0% 5.26%
Net Earnings $2.133M $21.97M $774.0K
YoY Change 175.58% 21871.0% 287.0%
Net Earnings / Revenue 7.26% 111.18% 3.91%
Basic Earnings Per Share $0.12 $0.91 -$3.90
Diluted Earnings Per Share $0.11 $0.79 -$3.90
COMMON SHARES
Basic Shares Outstanding 18.29M 276.6K
Diluted Shares Outstanding 20.21M 276.6K

Balance Sheet

Concept 2014 Q3 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.20M $13.50M $17.10M
YoY Change 228.65% -10.6% 0.0%
Cash & Equivalents $56.16M $13.52M $13.52M
Short-Term Investments
Other Short-Term Assets $7.800M $4.700M $800.0K
YoY Change 875.0% 840.0% 33.33%
Inventory $7.300M $4.248M $4.100M
Prepaid Expenses
Receivables $18.10M $10.23M $9.700M
Other Receivables $0.00 $100.0K $0.00
Total Short-Term Assets $89.30M $32.80M $31.60M
YoY Change 182.59% 22.85% 12.46%
LONG-TERM ASSETS
Property, Plant & Equipment $31.10M $29.72M $28.60M
YoY Change 8.74% 46.41% 55.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $16.50M $1.765M $300.0K
YoY Change 5400.0% 1665.0% 200.0%
Total Long-Term Assets $47.90M $1.765M $29.30M
YoY Change 63.48% -91.56% 53.4%
TOTAL ASSETS
Total Short-Term Assets $89.30M $32.80M $31.60M
Total Long-Term Assets $47.90M $1.765M $29.30M
Total Assets $137.2M $82.40M $60.90M
YoY Change 125.29% 73.1% 29.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.20M $8.800M $11.50M
YoY Change -2.61% 46.67% 43.75%
Accrued Expenses $3.700M $2.900M
YoY Change 20.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $267.0K $5.258M $5.400M
YoY Change -95.06% 34.82% 50.0%
Total Short-Term Liabilities $20.48M $18.83M $19.20M
YoY Change 6.64% 36.43% 50.0%
LONG-TERM LIABILITIES
Long-Term Debt $391.0K $5.391M $6.600M
YoY Change -94.08% 5.71% 8.2%
Other Long-Term Liabilities $2.400M $455.0K $800.0K
YoY Change 200.0% 127.5% 300.0%
Total Long-Term Liabilities $391.0K $5.846M $7.400M
YoY Change -94.72% 10.3% 17.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.48M $18.83M $19.20M
Total Long-Term Liabilities $391.0K $5.846M $7.400M
Total Liabilities $23.25M $26.10M $26.70M
YoY Change -12.93% 37.36% 40.53%
SHAREHOLDERS EQUITY
Retained Earnings -$58.21M -$62.62M
YoY Change
Common Stock $18.00K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $113.9M -$62.37M $34.20M
YoY Change
Total Liabilities & Shareholders Equity $137.2M $82.40M $60.90M
YoY Change 125.21% 73.1% 29.03%

Cashflow Statement

Concept 2014 Q3 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income $2.133M $21.97M $774.0K
YoY Change 175.58% 21871.0% 287.0%
Depreciation, Depletion And Amortization $3.148M $2.540M $2.274M
YoY Change 38.43% 66.01% 83.39%
Cash From Operating Activities $3.210M $1.990M $4.600M
YoY Change -30.22% 8.74% -3166.67%
INVESTING ACTIVITIES
Capital Expenditures -$460.0K -$490.0K -$1.220M
YoY Change -62.3% 16.67% 62.67%
Acquisitions
YoY Change
Other Investing Activities -$3.380M -$3.160M -$4.170M
YoY Change -18.94% 6.76% 47.87%
Cash From Investing Activities -$3.840M -$3.640M -$5.390M
YoY Change -28.76% 7.69% 51.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.25M -1.890M 3.680M
YoY Change -432.88% 329.55% -483.33%
NET CHANGE
Cash From Operating Activities 3.210M 1.990M 4.600M
Cash From Investing Activities -3.840M -3.640M -5.390M
Cash From Financing Activities -12.25M -1.890M 3.680M
Net Change In Cash -12.88M -3.540M 2.890M
YoY Change -545.67% 77.89% -161.88%
FREE CASH FLOW
Cash From Operating Activities $3.210M $1.990M $4.600M
Capital Expenditures -$460.0K -$490.0K -$1.220M
Free Cash Flow $3.670M $2.480M $5.820M
YoY Change -36.94% 10.22% 870.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Assets
Assets
82397000
CY2014Q3 ingn Land And Building
LandAndBuilding
126000
CY2013Q4 ingn Construction In Process
ConstructionInProcess
1093000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
45678000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15956000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29722000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
215000
CY2014Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
16427000
CY2013Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
17865000
CY2013Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1765000
CY2014Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
6360000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3390000
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2013Q4 ingn Rental Equipment Allowance
RentalEquipmentAllowance
157000
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
66666
CY2014Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
267000
CY2014Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2647000
CY2013Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
118671000
us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
28673000
CY2014Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
12000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
209000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8715000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3408000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2133000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1077000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4320000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1895000
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
7512000
ingn Warrants Converted To Temporary Equity Value
WarrantsConvertedToTemporaryEquityValue
593000
us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
987000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28369000
us-gaap Revenues
Revenues
83419000
CY2013Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
3923000
CY2013Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
37573000
CY2014Q3 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
45532000
us-gaap Operating Expenses
OperatingExpenses
24905000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
113906000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137153000
us-gaap Operating Income Loss
OperatingIncomeLoss
9079000
us-gaap Operating Income Loss
OperatingIncomeLoss
3911000
us-gaap Revenues
Revenues
55681000
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20213102
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
276618
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5995000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18286208
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
886000
us-gaap Operating Expenses
OperatingExpenses
32622000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9796000
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.90
CY2013Q3 us-gaap Revenues
Revenues
19777000
CY2014Q3 us-gaap Revenues
Revenues
29393000
CY2014Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10146000
CY2013Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6751000
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
276618
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
413000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8779000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3615000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
151000
us-gaap Net Income Loss
NetIncomeLoss
3464000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-296000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3532000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2312000
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4550000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4697000
us-gaap Gross Profit
GrossProfit
28816000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17656000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
11082000
us-gaap Inventory Write Down
InventoryWriteDown
125000
us-gaap Inventory Write Down
InventoryWriteDown
92000
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18436802
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
280974
CY2014Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11201000
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9219000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3732000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2898000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
247000
CY2014Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
183000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
172100000
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
66666
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2013Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
250000
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18436802
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
280974
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5258000
CY2014Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
669000
CY2013Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
420000
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1959000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1487000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20475000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19282000
CY2014Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
503000
CY2013Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
389000
CY2013Q4 ingn Preferred Stock Warrant Liability
PreferredStockWarrantLiability
260000
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1878000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
776000
CY2014Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
391000
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5391000
CY2014Q3 us-gaap Liabilities
Liabilities
23247000
CY2013Q4 us-gaap Liabilities
Liabilities
26098000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
18000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-87000
CY2014Q3 us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
2752000
us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
4921000
CY2013Q3 us-gaap Cost Of Services Depreciation
CostOfServicesDepreciation
1955000
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.90
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58212000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62620000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-62372000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82397000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
8756000
us-gaap Sales Revenue Net
SalesRevenueNet
54746000
us-gaap Sales Revenue Net
SalesRevenueNet
33780000
CY2014Q3 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
9968000
CY2013Q3 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
7643000
us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
21901000
CY2014Q3 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
4598000
CY2013Q3 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
3384000
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
14744000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1817000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3567000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12654000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13292000
CY2014Q3 us-gaap Interest Expense
InterestExpense
104000
CY2014Q3 us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
367000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3208000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
449000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
404000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1341000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
2133000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
774000
us-gaap Net Income Loss
NetIncomeLoss
5307000
CY2013Q3 ingn Deemed Dividend On Redeemable Convertible Preferred Stock
DeemedDividendOnRedeemableConvertiblePreferredStock
1851000
ingn Deemed Dividend On Redeemable Convertible Preferred Stock
DeemedDividendOnRedeemableConvertiblePreferredStock
987000
ingn Deemed Dividend On Redeemable Convertible Preferred Stock
DeemedDividendOnRedeemableConvertiblePreferredStock
5359000
CY2013Q3 us-gaap Interest Expense
InterestExpense
113000
us-gaap Interest Expense
InterestExpense
440000
us-gaap Interest Expense
InterestExpense
312000
CY2014Q3 us-gaap Interest Income Other
InterestIncomeOther
10000
CY2013Q3 us-gaap Interest Income Other
InterestIncomeOther
3000
us-gaap Interest Income Other
InterestIncomeOther
28000
us-gaap Interest Income Other
InterestIncomeOther
9000
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-41000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-36000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
202000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-93000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-69000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-364000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3474000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
817000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
229000
ingn Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
76000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
120251000
CY2014Q3 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
us-gaap Share Based Compensation
ShareBasedCompensation
1123000
ingn Reclassification Of Warrant Liability
ReclassificationOfWarrantLiability
22000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
120251000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
49844000
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-1203000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2718000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
834000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
447000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
363000
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-330000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-85000
us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
2558000
us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
1090000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1201000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1353000
ingn Provision For Rental Revenue Adjustments
ProvisionForRentalRevenueAdjustments
5530000
ingn Provision For Rental Revenue Adjustments
ProvisionForRentalRevenueAdjustments
4057000
us-gaap Share Based Compensation
ShareBasedCompensation
116000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-999000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17119000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9176000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
130000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
134000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
124000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1982000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
396000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1574000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
867000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2647000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
100000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11368000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
11478000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
184000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
7000
ingn Payment To Produce Rental Equipment
PaymentToProduceRentalEquipment
10132000
ingn Payment To Produce Rental Equipment
PaymentToProduceRentalEquipment
11918000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1060000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2572000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11376000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14497000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6000000
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
467000
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
1875000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
229000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
56471000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4942000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
413000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
130000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
159000
us-gaap Repayments Of Debt
RepaymentsOfDebt
15861000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2750000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
42647000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4966000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
42639000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1947000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13521000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15112000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56160000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17059000
us-gaap Interest Paid
InterestPaid
478000
us-gaap Interest Paid
InterestPaid
307000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1673000
us-gaap Income Taxes Paid
IncomeTaxesPaid
124000
us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
5359000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. General </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of presentation</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair presentation for each of the periods presented.&#160;The results of operations for interim periods are not necessarily indicative of results to be achieved for full fiscal years or other interim periods.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November&#160;27, 2001. The Company is a medical technology company that develops, manufactures and markets innovative oxygen concentrators used for supplemental long-term oxygen therapy by patients with chronic obstructive pulmonary disease, or COPD, and other chronic respiratory conditions. The Company&#8217;s proprietary Inogen One systems are designed to address the quality-of-life and other shortcomings of the traditional oxygen therapy model, which Inogen calls the delivery model. Traditionally, oxygen therapy patients have relied upon stationary oxygen concentrator systems in the home in conjunction with regular deliveries of oxygen tanks or cylinders for ambulatory, or mobile, use, limiting their mobility and requiring them to plan activities outside of their homes around delivery schedules and a finite oxygen supply.&nbsp;&nbsp;The Company&#8217;s Inogen One systems concentrate the air around them to offer a single source of supplemental oxygen anytime, anywhere from devices weighing approximately five to seven pounds. Inogen&#8217;s products eliminate the need for oxygen deliveries, as well as regular use of a stationary concentrator, thereby improving patient quality-of-life and fostering patient mobility. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As contemplated by the Securities and Exchange Commission (SEC) under Rule&#160;10-01 of Regulation S-X, the accompanying financial statements and related footnotes have been condensed and do not contain certain information that will be included in the Company&#8217;s annual financial statements and footnotes thereto.&#160;For further information refer to the financial statements and related footnotes included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2013 filed with the SEC on April 1, 2014 (Annual Report).</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Use of estimates<font style="font-weight:normal;font-style:normal;"> </font></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these condensed financial statements and accompanying notes.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable.&#160;Significant areas requiring the use of management estimates relate to inventory and rental asset valuations and write-downs, accounts receivable reserves and allowance for bad debts, returns and adjustments, stock compensation expense, impairment assessments, depreciation and amortization, income tax provision and uncertain tax positions, fair value of financial instruments, and fair values of acquired intangibles.&nbsp;&nbsp;Actual results could differ materially from these estimates.</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Reclassifications</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to prior years financial statements to conform to current period financial statement presentation with no effect on previously reported financial position, results of operations or cash flows.</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Initial public offering (IPO)</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company completed an initial public offering on February 20, 2014, and sold 3,529,411 shares to the public for $16.00 per share.&nbsp;&nbsp;In addition, the selling shareholders sold 981,902 shares for a combined total of 4,511,313 shares sold in the offering.&nbsp;&nbsp;The Company netted approximately $49,668 after the underwriters discount and other associated expenses.&nbsp;&nbsp;In connection with the completion of our IPO, the Company&#8217;s outstanding redeemable convertible preferred stock and non-redeemable preferred stock were all converted to common stock.&nbsp;&nbsp;As of September 30, 2014, the Company had 18,436,802 shares of common stock outstanding.</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;font-style:italic;"> Revenue from contracts with customers</font></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the Company&#8217;s pending adoption of ASU 2014-09 on the Company&#8217;s consolidated financial statements and has not yet determined the method by which the Company will adopt the standard in 2017.</p></div>
CY2014Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.386
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.391
us-gaap Use Of Estimates
UseOfEstimates
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Use of estimates<font style="font-weight:normal;font-style:normal;"> </font></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s condensed financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these condensed financial statements and accompanying notes.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable.&#160;Significant areas requiring the use of management estimates relate to inventory and rental asset valuations and write-downs, accounts receivable reserves and allowance for bad debts, returns and adjustments, stock compensation expense, impairment assessments, depreciation and amortization, income tax provision and uncertain tax positions, fair value of financial instruments, and fair values of acquired intangibles.&nbsp;&nbsp;Actual results could differ materially from these estimates.</p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c)</font></p></td> <td valign="top" style="width:95.46%;"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Reclassifications</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to prior years financial statements to conform to current period financial statement presentation with no effect on previously reported financial position, results of operations or cash flows.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents and short-term investments to date. </p></div>
CY2014Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
891000
CY2014Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1172000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.66
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.33
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.09
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.50
CY2013Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
809000
ingn Number Of Products Qualify As Separate Units
NumberOfProductsQualifyAsSeparateUnits
2
ingn Standard Product Warranty
StandardProductWarranty
P3Y
us-gaap Extended Product Warranty Description
ExtendedProductWarrantyDescription
Lifetime of the patient
us-gaap Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Method
RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceMethod
The Company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, the Company estimates on average all patients will succumb to their disease within five years.
us-gaap Revenue Recognition New Accounting Pronouncement Timing
RevenueRecognitionNewAccountingPronouncementTiming
30-day period
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
260000
CY2013Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
260000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
-148000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
36000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
76000
CY2014Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
0
CY2014Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
3410000
CY2013Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1435000
CY2014Q3 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
6058000
CY2013Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
3783000
CY2014Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1456000
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
565000
CY2013Q3 us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
251000
us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
1157000
us-gaap Cost Of Property Repairs And Maintenance
CostOfPropertyRepairsAndMaintenance
707000
CY2014Q3 us-gaap Property Plant And Equipment Salvage Value
PropertyPlantAndEquipmentSalvageValue
0
CY2014Q3 us-gaap Depreciation
Depreciation
3148000
CY2013Q3 us-gaap Depreciation
Depreciation
2274000
us-gaap Depreciation
Depreciation
8654000
us-gaap Depreciation
Depreciation
5792000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2013Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
3:1
ingn Effective Date Of Reverse Stock Split
EffectiveDateOfReverseStockSplit
2013-11-12
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4411763
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
16.00
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
766000
CY2012Q4 us-gaap Line Of Credit Facility Commitment Fee Percentage
LineOfCreditFacilityCommitmentFeePercentage
0.01
CY2014Q1 ingn Common Stock Purchased By Underwriters
CommonStockPurchasedByUnderwriters
99550
CY2014Q3 ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
2133000
CY2013Q3 ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
-1077000
ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
4320000
ingn Net Income Loss Available To Common Stockholders Before Preferred Rights Dividend
NetIncomeLossAvailableToCommonStockholdersBeforePreferredRightsDividend
-1895000
CY2014Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
CY2013Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
563000
CY2014Q3 ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
2133000
CY2013Q3 ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
-1077000
ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
3757000
ingn Net Income Loss Available To Common Stockholders Basic Net Of Undistributed Earnings To Preferred Stock
NetIncomeLossAvailableToCommonStockholdersBasicNetOfUndistributedEarningsToPreferredStock
-1895000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Diluted
UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
507000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2133000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1077000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
3813000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1895000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P2Y
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
45000
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
68000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
203000
CY2014Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1165000
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
981000
CY2012Q4 us-gaap Line Of Credit Facility Commitment Fee Amount
LineOfCreditFacilityCommitmentFeeAmount
120000
CY2014Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
12000000
CY2014Q3 ingn Outstanding Term Loan And Accrued Interest Paid
OutstandingTermLoanAndAccruedInterestPaid
11600000
CY2014Q3 us-gaap Long Term Debt
LongTermDebt
658000
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
10649000
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
44000
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
299000
CY2014Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
315000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
214000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
738000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
336000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
328000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
315000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
313000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2244000
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
182000
CY2013Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
223000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
569000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
690000
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
447000
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
814000
CY2013 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
533000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
296000
CY2013 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
322000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
747000
CY2013 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
493000
us-gaap Significant Change In Unrecognized Tax Benefits Nature Of Event
SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent
The Company does not expect any material changes to unrecognized tax benefits in the next 12 months, and has not incurred any tax related penalties or interest.
CY2013 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.05
CY2013 ingn Preferred Stock Date Of Issuance
PreferredStockDateOfIssuance
May 2002
CY2013Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.053
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.042
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22909000
CY2013 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
21587000
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2328675
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
644916
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
243828
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
46636
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4799
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2678328
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1574614
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2562500
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.94
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.21
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.40
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y15D
CY2013Q4 ingn Redeemable Convertible Preferred Stock Conversion Ratio
RedeemableConvertiblePreferredStockConversionRatio
1.01706
CY2013Q4 us-gaap Temporary Equity Liquidation Preference Per Share
TemporaryEquityLiquidationPreferencePerShare
3.750
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
632694
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
12222
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.62
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y6M29D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M22D
CY2013 ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare
10.23
ingn Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare
15.11
CY2014Q3 ingn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue
18.40
CY2014Q3 ingn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue
15.21
ingn Share Based Compensation Expense Reduced Rate For Estimated Forfeiture
ShareBasedCompensationExpenseReducedRateForEstimatedForfeiture
0.0666
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
457000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
65000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5055000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1370000
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
263463
CY2014Q3 ingn Preferred Stock Warrant Liability
PreferredStockWarrantLiability
0
CY2014Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0

Files In Submission

Name View Source Status
0001564590-14-005531-index-headers.html Edgar Link pending
0001564590-14-005531-index.html Edgar Link pending
0001564590-14-005531.txt Edgar Link pending
0001564590-14-005531-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ingn-10q_20140930.htm Edgar Link pending
ingn-20140930.xml Edgar Link completed
ingn-20140930.xsd Edgar Link pending
ingn-20140930_cal.xml Edgar Link unprocessable
ingn-20140930_def.xml Edgar Link unprocessable
ingn-20140930_lab.xml Edgar Link unprocessable
ingn-20140930_pre.xml Edgar Link unprocessable
ingn-ex311_201409307.htm Edgar Link pending
ingn-ex312_201409309.htm Edgar Link pending
ingn-ex321_201409306.htm Edgar Link pending
ingn-ex322_201409308.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending